VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Catalyst Pharmaceuticals Executive Compensation (FY24)

CPRX · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Richard Daly
Latest say-on-pay support
=
May 20, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Catalyst Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): May 23, 2025
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Catalyst Pharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
241 figures on this page: 232 cited to the filing that reported them, 9 calculated from figures it prints. See the citations

More on Catalyst Pharmaceuticals

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Patrick J. McEnany → Richard Daly
Say-on-pay support: 93.9% → 92.7% (1.2 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Catalyst Pharmaceuticals' chief executive and what were they paid?
Richard Daly, President and CEO, received $7,774,160 in total compensation for fiscal 2024.
What was Catalyst Pharmaceuticals' say-on-pay result?
Shareholders supported the say-on-pay proposal with 92.7% of votes cast for or against in favor at the meeting held May 20, 2025 for fiscal 2024.
Which companies are in Catalyst Pharmaceuticals' peer group?
The disclosed peer group names Acadia Pharmaceuticals Inc., Amicus Therapeutics, Inc., Amphastar Pharmaceuticals, Inc., Ani Pharmaceuticals, Inc. and Collegium Pharmaceutical, Inc., among others.
What is Catalyst Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 21:1 for fiscal 2024, against median employee compensation of $370,800.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Patrick J. McEnany
Former President and Chief Executive Officer
Departed during or after this year
◇◇◇◇———◇
Steven Miller
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
◇◇◇◇——◇◇
Jeffrey Del Carmen
Executive Vice President, Chief Commercial Officer
◇◇◇◇——◇◇
Preethi Sundaram
Chief Strategy Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Steven Miller
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
◇◇◇◇——◇◇
Jeffrey Del Carmen
Executive Vice President, Chief Commercial Officer
◇◇◇◇——◇◇
Patrick J. McEnany
Former President and Chief Executive Officer
Departed during or after this year
◇◇◇◇———◇
Preethi Sundaram
Chief Strategy Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Daly
President and CEO
◇◇◇◇——◇◇
Michael Kalb
EVP and CFO
◇◇◇◇——◇◇
Steven Miller
COO and CSO
◇◇◇◇——◇◇
Jeffrey Del Carmen
CCO
◇◇◇◇——◇◇
Preethi Sundaram
Chief Strategy Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jeffrey Del CarmenOPTION◇——◇—◇◇
Michael W. KalbOPTION◇——◇—◇◇
Michael W. KalbOPTION◇——◇—◇◇
Preethi SundaramOPTION◇——◇—◇◇
Richard J. DalyOPTION◇——◇—◇◇
Steven R. MillerOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Richard DalyOption◇—◇10/18/2030
Option◇—◇11/21/2031
Option◇—◇12/27/2029
Michael KalbOption◇—◇01/01/2031
Option◇—◇11/21/2031
Steven MillerOption◇—◇11/21/2031
Option◇—◇12/08/3030
Option◇—◇12/27/2029
Preethi SundaramOption◇—◇11/21/2031
Option◇—◇12/08/2030
Option◇—◇07/06/2028
Option◇—◇12/27/2029
Jeffrey Del CarmenOption◇—◇11/21/2031
Option◇—◇12/08/2030
Option◇—◇06/23/2027
Option◇—◇12/27/2029
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Jeffrey Del Carmen
CCO · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Michael Kalb
EVP and CFO · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Preethi Sundaram
Chief Strategy Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Richard Daly
President and CEO · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Steven Miller
COO and CSO · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Patrick J. McEnany
Board chair
◇◇————◇
Molly Harper
Lead independent director
◇◇————◇
Charles B. O'Keeffe
◇◇————◇
Donald A. Denkhaus
◇◇————◇
Tamar Thompson
◇◇————◇
David S. Tierney
◇◇————◇
Richard J. Daly served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Stock options and RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Acadia Pharmaceuticals Inc. ACAD
  • Amicus Therapeutics, Inc. FOLD
  • Amphastar Pharmaceuticals, Inc. AMPH
  • Ani Pharmaceuticals, Inc. ANIP
  • Collegium Pharmaceutical, Inc. COLL
  • Corcept Therapeutics Incorporated CORT
  • Dynavax Technologies Corporation DVAX
  • Halozyme Therapeutics, Inc. HALO
  • Harmony Biosciences Holdings, Inc. HRMY
  • Insmed Incorporated INSM
  • Ionis Pharmaceuticals, Inc. IONS
  • Ironwood Pharmaceuticals, Inc. IRWD
  • Pacira BioSciences, Inc. PCRX
  • PTC Therapeutics, Inc. PTCT
  • Supernus Pharmaceutials, Inc. symbol not shown
  • Ultragenyx Pharmaceutical, Inc. RARE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024May 20, 2025=◇◇◇
2023May 21, 2024=◇◇◇
2022August 22, 2023=◇◇◇
2021September 19, 2022=◇◇◇
2020December 3, 2021=◇◇◇
2019August 20, 2020=◇◇◇
2018May 23, 2019=◇◇◇
2017May 24, 2018=◇◇◇
2015June 6, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Richard Daly (President and CEO), FY2024 total compensation $7,774,160 (base salary $750,000) [exec_comp, SEC accession 0001193125-25-079097, filed 2025-04-11]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Catalyst Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Catalyst Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Catalyst Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Catalyst Pharmaceuticals' disclosed peer group is defensible, who names Catalyst Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
241 figures on this page: 232 cited to the filing that reported them, 9 calculated from figures it prints.
232 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001193125-25-125872
  2. 0001193125-25-079097
    CEO Pay Ratio · Compensation Discussion and Analysis · Compensation of Directors · Grants of Plan-Based Awards · and 1 more section
  3. 0001193125-24-144049
    240 2,859,403 168,196 11,817,471 3.
  4. 0001193125-24-091926
    Summary Compensation Table
  5. 0001193125-23-221544
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-22-247180
  7. 0001193125-21-348019
  8. 0001193125-20-227098
  9. 0001193125-19-159724
  10. 0001193125-18-175523
  11. 0001193125-16-615375
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Catalyst Pharmaceuticals executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/CPRX (accessed 2026).
Short form: data: Velarion

The paid brief for Catalyst Pharmaceuticals

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Catalyst Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Catalyst Pharmaceuticals discloses

The companies named in CPRX's own disclosed peer group.

Acadia Pharmaceuticals Inc.Amicus Therapeutics, Inc.Amphastar Pharmaceuticals, Inc.Ani Pharmaceuticals, Inc.Collegium Pharmaceutical, Inc.Corcept Therapeutics IncorporatedDynavax Technologies CorporationHalozyme Therapeutics, Inc.Harmony Biosciences Holdings, Inc.Insmed IncorporatedIonis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Pacira BioSciences, Inc.PTC Therapeutics, Inc.Ultragenyx Pharmaceutical, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy